CogState Ltd
ASX:CGS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.02
2.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
CogState Ltd
Cogstate Ltd. is a global cognitive science company. The firm provides computerized cognitive tests across various domains and support electronic clinical outcome assessment (eCOA) solutions. The firm's segment includes Clinical trials, Healthcare and Research. In the Clinical trials segment, the Company's technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians to assess cognitive decline. Research segment offers various research studies and academic collaborations across various indication of diseases.
Cogstate Ltd. is a global cognitive science company. The firm provides computerized cognitive tests across various domains and support electronic clinical outcome assessment (eCOA) solutions. The firm's segment includes Clinical trials, Healthcare and Research. In the Clinical trials segment, the Company's technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians to assess cognitive decline. Research segment offers various research studies and academic collaborations across various indication of diseases.
Record Revenue: Cogstate delivered $45 million in revenue for FY2022, up 38% year-over-year, driven mainly by growth in Alzheimer's clinical trial contracts.
Margin Expansion: EBIT margin improved to 23%–24% of revenue, exceeding previous guidance, reflecting strong operating leverage and cost control.
Contracted Backlog: Revenue backlog reached $139 million at June 30, 2022, up 37% year-over-year, positioning the company for future growth.
Alzheimer's Focus: 84% of FY2022 sales contracts were related to Alzheimer's trials, and upcoming Phase III data readouts from key drugs could be major catalysts.
Strong Cash Position: Net cash increased to $28.7 million, with over $30.5 million in total cash and $9.7 million in operating cash inflow for the year.
Decentralized Trials: Adoption of virtual and home-based clinical trials is accelerating, benefiting Cogstate’s digital assessment technology.
Guidance Maintained: Management expects EBIT margin of 20%–24% to continue, with potential upside if the healthcare segment grows.
